MEDSENIC

BioSenic Advances Autoimmune Pipeline and Explores Strategic M&A Opportunities

- BioSenic is actively pursuing strategic mergers and acquisitions to expand its asset portfolio, focusing on opportunities within the biopharmaceutical sector. - Positive Phase II clinical data for arsenic trioxide (ATO) in chronic Graft-versus-Host Disease (cGvHD) supports plans for a Phase III trial, pending FDA review. - Clinical trials for Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) are in the planning stages, contingent on securing partnerships or out-licensing agreements.